Abcon Therapeutics was formed as a Cleveland Clinic spin-off with an initial investment from the Cleveland Clinic. The Company is currently raising its Series A round of financing. The Company has also received STTR grants from the National Eye Institute and the National Cancer Institute. More recently, Abcon entered into a milestone driven partnership with the NExT program of the National Cancer Institute to advance its lead product, ATX101, through preclinical development and into the clinic.
